Combined-modality therapy for esophageal cancer: Phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy

Seminars in Oncology

Volumn 24, Issue 6 SUPPL. 19, 1997, Pages

  Weiner, L M ^a   Colarusso, P ^a   Goldberg, M ^a   Dresler, C ^a   Coia, L R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; ARTICLE; BACTERIAL INFECTION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ESOPHAGITIS; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MALE; MEGAVOLTAGE RADIATION; NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 0031473948     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)